What's in Samsung Bioepis Co., Ltd.'s pipeline?

Samsung Bioepis Co., Ltd. has 20 drugs in our index: 3 marketed, 0 filed, 5 in Phase 3, 1 in Phase 2, 11 in Phase 1.

Which companies overlap with Samsung Bioepis Co., Ltd.'s portfolio?

Top competitors by shared drug class: Hoffmann-La Roche, Pfizer, Amgen, Celltrion, Centocor, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/samsung-bioepis-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Samsung Bioepis Co., Ltd. — Portfolio Competitive Intelligence Brief

Samsung Bioepis Co., Ltd. pipeline: 3 marketed, 0 filed, 5 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 5 Phase 3 1 Phase 2 11 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
SB5 (Adalimumab Biosimilar)	SB5 (Adalimumab Biosimilar)	marketed	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (tumor necrosis factor-alpha)	Immunology
SB5	SB5	marketed	TNF-α inhibitor (monoclonal antibody); biosimilar	TNF-α (tumor necrosis factor-alpha)	Immunology; Rheumatology
Lucentis (ranibizumab)	Lucentis (ranibizumab)	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)	Ophthalmology
Herceptin (trastuzuamb)	Herceptin (trastuzuamb)	phase 3	HER2-targeted monoclonal antibody	HER2 (human epidermal growth factor receptor 2)	Oncology
SB8	SB8	phase 3	VEGF inhibitor (monoclonal antibody) / Bevacizumab biosimilar	VEGF (Vascular Endothelial Growth Factor)	Oncology
Soliris (eculizumab)	Soliris (eculizumab)	phase 3	Monoclonal antibody	C5	Immunology
Prolia® (Denosumab)	Prolia® (Denosumab)	phase 3	Monoclonal antibody	RANKL	Osteoporosis, Bone-related disorders
SB27	SB27	phase 3	TNF-alpha inhibitor	TNF-alpha	Rheumatology

Therapeutic area mix

Immunology · 3
Oncology · 2
Immunology; Rheumatology · 1
Ophthalmology · 1
Osteoporosis, Bone-related disorders · 1
Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hoffmann-La Roche · 3 shared drug classes
Pfizer · 2 shared drug classes
Amgen · 2 shared drug classes
Celltrion · 2 shared drug classes
Centocor, Inc. · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Alvotech Swiss AG · 2 shared drug classes
Sandoz · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Samsung Bioepis Co., Ltd.:

Cite this brief

Drug Landscape (2026). Samsung Bioepis Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/samsung-bioepis-co-ltd. Accessed 2026-05-16.